Literature DB >> 16445299

Bayesian methods for evidence synthesis in cost-effectiveness analysis.

A E Ades1, Mark Sculpher, Alex Sutton, Keith Abrams, Nicola Cooper, Nicky Welton, Guobing Lu.   

Abstract

Recently, health systems internationally have begun to use cost-effectiveness research as formal inputs into decisions about which interventions and programmes should be funded from collective resources. This process has raised some important methodological questions for this area of research. This paper considers one set of issues related to the synthesis of effectiveness evidence for use in decision-analytic cost-effectiveness (CE) models, namely the need for the synthesis of all sources of available evidence, although these may not 'fit neatly' into a CE model. Commonly encountered problems include the absence of head-to-head trial evidence comparing all options under comparison, the presence of multiple endpoints from trials and different follow-up periods. Full evidence synthesis for CE analysis also needs to consider treatment effects between patient subpopulations and the use of nonrandomised evidence. Bayesian statistical methods represent a valuable set of analytical tools to utilise indirect evidence and can make a powerful contribution to the decision-analytic approach to CE analysis. This paper provides a worked example and a general overview of these methods with particular emphasis on their use in economic evaluation.

Entities:  

Mesh:

Year:  2006        PMID: 16445299     DOI: 10.2165/00019053-200624010-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  56 in total

1.  Generalized synthesis of evidence and the threat of dissemination bias. the example of electronic fetal heart rate monitoring (EFM).

Authors:  Alexander J Sutton; Keith R Abrams; David R Jones
Journal:  J Clin Epidemiol       Date:  2002-10       Impact factor: 6.437

2.  Multivariate meta-analysis.

Authors:  In-Sun Nam; Kerrie Mengersen; Paul Garthwaite
Journal:  Stat Med       Date:  2003-07-30       Impact factor: 2.373

3.  Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?

Authors:  Stephen Palmer; Mark Sculpher; Zoe Philips; Mike Robinson; Laura Ginnelly; Ameet Bakhai; Keith Abrams; Nicola Cooper; Chris Packham; Khaled Alfakih; Alistair Hall; David Gray
Journal:  Int J Cardiol       Date:  2005-04-20       Impact factor: 4.164

4.  How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS.

Authors:  Paul C Lambert; Alex J Sutton; Paul R Burton; Keith R Abrams; David R Jones
Journal:  Stat Med       Date:  2005-08-15       Impact factor: 2.373

5.  A rational framework for decision making by the National Institute For Clinical Excellence (NICE).

Authors:  Karl Claxton; Mark Sculpher; Michael Drummond
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

Review 6.  Meta-analytic tools for medical decision making: a practical guide.

Authors:  V Hasselblad; D C McCrory
Journal:  Med Decis Making       Date:  1995 Jan-Mar       Impact factor: 2.583

7.  Assessing apparent treatment--covariate interactions in randomized clinical trials.

Authors:  D P Byar
Journal:  Stat Med       Date:  1985 Jul-Sep       Impact factor: 2.373

8.  Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials.

Authors:  H C Bucher; P Hengstler; C Schindler; G H Guyatt
Journal:  BMJ       Date:  2000-07-08

9.  Multiple-outcome meta-analysis of clinical trials.

Authors:  C S Berkey; J J Anderson; D C Hoaglin
Journal:  Stat Med       Date:  1996-03-15       Impact factor: 2.373

Review 10.  Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials.

Authors:  Yazdan Yazdanpanah; Daouda Sissoko; Matthias Egger; Yves Mouton; Marcel Zwahlen; Geneviève Chêne
Journal:  BMJ       Date:  2004-01-23
View more
  140 in total

1.  No head-to-head trial? simulate the missing arms.

Authors:  J Jaime Caro; K Jack Ishak
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Authors:  Christine M Nguyen; Mark Bounthavong; Margaret A S Mendes; Melissa L D Christopher; Josephine N Tran; Rashid Kazerooni; Anthony P Morreale
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

Review 3.  Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions?

Authors:  Mark J Sculpher; Michael F Drummond
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Better analysis for better decisions: has pharmacoeconomics come of age?

Authors:  Michael Drummond; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 5.  The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis.

Authors:  Grant H Skrepnek
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 6.  Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis.

Authors:  Yolanda Bravo Vergel; Stephen Palmer; Christian Asseburg; Elisabeth Fenwick; Mark de Belder; Keith Abrams; Mark Sculpher
Journal:  Heart       Date:  2007-08-23       Impact factor: 5.994

7.  A choice that matters? Smulation study on the impact of direct meta-analysis methods on health economic outcomes.

Authors:  Pepijn Vemer; Maiwenn J Al; Mark Oppe; Maureen P M H Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

Review 8.  Use of indirect and mixed treatment comparisons for technology assessment.

Authors:  Alex Sutton; A E Ades; Nicola Cooper; Keith Abrams
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 9.  Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.

Authors:  Glen S Hazlewood; Cheryl Barnabe; George Tomlinson; Deborah Marshall; Daniel J A Devoe; Claire Bombardier
Journal:  Cochrane Database Syst Rev       Date:  2016-08-29

Review 10.  Is Local Infiltration Analgesia Superior to Peripheral Nerve Blockade for Pain Management After THA: A Network Meta-analysis.

Authors:  José H Jiménez-Almonte; Cody C Wyles; Saranya P Wyles; German A Norambuena-Morales; Pedro J Báez; Mohammad H Murad; Rafael J Sierra
Journal:  Clin Orthop Relat Res       Date:  2015-11-16       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.